Bioventus Inc.
BVSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Bioventus Inc. (BVS) is listed under Medical Devices. With a market capitalization of $1.02B, it sits in small-cap territory. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Market Cap
$1.02B
Beta
0.64
P/E (TTM)
19.18
P/E (Fwd)
16.26
EPS (TTM)
$0.78
EPS (Fwd)
$0.92
ROE
25.7%
ROA
5.5%
Cash
$30.4M
Total Debt
$263.7M
Free CF
$67.8M
52W Change
123.0%
Annual Financials
Cash vs Debt
Where BVS stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BVS finished 17.18% above its 150-day moving average ($11.35) and 25.83% above its 200-day moving average ($10.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BVS overbought or oversold?
At the October 19, 2026 close, BVS's RSI(14) was 40.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bioventus Inc. carries $263.7M in total debt against $30.4M in cash reserves — debt is roughly 8.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $67.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 25.7% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $512.1M to $568.1M.
BVS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Bioventus Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bioventus Inc. and its sector.